Clinical

Lower antioxidant intake is associated with an increased risk of rheumatoid arthritis (RA) in women of childbearing age with endometriosis (EM), highlighting the importance of antioxidant intake for managing EM-related RA.

In this interview, Chris Pagnani, MD, PC, shares how telemedicine is transforming mental health care by making psychiatry accessible for patients, especially for those in health care deserts.

Consistent with previous observations, overall survival and progression-free survival remained strong at the follow-up point.

Promising results presented at the Academy of Managed Care Pharmacy 2024 annual meeting support the safety and efficacy of bimekizumab treatment in patients with active psoriatic arthritis who had previously shown inadequate response or intolerance to tumor necrosis factor inhibitors.

More than 20 years of gene therapy clinical research have led to etranacogene dezaparvovec’s use in hemophilia B, according to authors of a recent review—and it takes its place in a line of current and potentially many future genomic medicines for a range of diseases.

Blood-based screening for colorectal cancer (CRC) should only be used with patients who are not completing other endorsed screening options, according to a study.

In a presentation at the Greater Philadelphia Business Coalition on Health Women’s Health Summit, Shelly Lanning, cofounder and president of Visana Health, addressed the need for comprehensive approaches in women’s health care and their coverage options.

Data highlight substantial improvements in outcomes following allogeneic hematopoietic cell transplantation (allo-HCT) among older patients with acute myeloid leukemia (AML).

A predictive model using plasma proteins as biomarkers predicted hepatocellular carcinoma development more accurately than a model based on traditional lifestyle risk factors in a recent study.

Although histological transformation to diffuse large B-cell lymphoma (DLBCL) remains a common complication of follicular lymphoma, patient survival has increased significantly since the introduction of rituximab about 2 decades ago.

A new definition of rectal cancer in the Netherlands prompted reclassification of cancer as sigmoid tumors, which could lead to better treatment.

Data from the study showed that exa-cel prevented vaso-occlusive crises in all but 1 of the 30 evaluable patients for at least 12 months.

Older patients with chronic obstructive pulmonary disease (COPD) and anxiety exhibited exacerbated symptoms, increased comorbidities, and frequent acute exacerbations of COPD (AECOPD), emphasizing the need for routine psychiatric screening in COPD management.

In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.

Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among those with non-BRCA-like tumors, a study found.

COVID-19 and worsening myasthenia gravis (MG) were the most common treatment-emergent adverse events, the study found.

The Federal Trade Commission (FTC) issued letters to 10 companies to warn them that certain drug patents were improperly listed; the US Department of Agriculture (USDA) will begin testing ground beef for bird flu particles; rural Americans are more likely to die early from 1 of the 5 leading causes of death than those who live in urban areas.

A medical expert discusses the various types of bacteria and fungi that can grow in the lungs and sputum of bronchiectasis patients, such as Pseudomonas aeruginosa, emphasizing the importance of an individualized approach to treatment, and notes that while fungal cultures may be positive, they may not always be clinically significant.

The introduction of the Global Initiative for Asthma 2019 guidelines significantly improved treatment of children with mild asthma, according to one study.

Results from a study presented at the Academy of Managed Care Pharmacy 2024 annual meeting demonstrated sustained efficacy of bimekizumab compared with placebo in patients with non-radiographic and radiographic axial spondyloarthritis (axSpA) at week 52.

The multi-year collaboration aims to develop tolerizing vaccines for up to 3 autoimmune diseases.

The investigators said their new system makes it possible for researchers to leverage artificial intelligence even if they do not have expertise working with advanced software.

The study aimed to improve the understanding of lived experiences and the fear of recurrence among survivors of localized, stage 0 to IIA cutaneous melanoma.

Makers of medical tests will have about 4 years to show the FDA that their new offerings deliver accurate results; after previously decreasing for 27 years, US tuberculosis (TB) cases increased every year since 2020; a US district judge rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to the Medicare drug price negotiation program.

Investigators also examined which type of immunosuppression was associated with a higher likelihood of Kaposi sarcoma.

"Off the shelf" CAR T-cell therapies could offer a solution in chronic lymphocytic leukemia, where T-cell exhaustion creates treatment challenges.

A recent study suggests virtual reality and biofeedback training may be feasible and effective for patients with Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD).

These lifestyle improvements included adherence to the Mediterranean diet, improved frequency of healthy food consumption, increased physical activity, and quitting smoking, among other factors.

Michael Morse, MD, FACP, MHS, medical oncologist at Duke Cancer Center, explained the importance of managing toxicities in the changing hepatocellular carcinoma (HCC) treatment landscape to ensure patients have the best possible outcomes in the front line and beyond.

An overview of the treatments for chronic lymphocytic leukemia (CLL) and novel therapies on the horizon, including double and triple combination therapies, cellular therapies, and bispecific antibodies.